127 POSTER

Chemoradiotherapy for stage IV, unmetastatic, head and neck cancer. Preliminary results of a prospective, single-institutional, phase II trial

F. Arias de la Vega, R. Vera, M.A. Domínguez, E. Oria, P. Romero, E. Villafranca, E. Martínez, J.J. Illarramendi, A. Manterola, J.I. Arrarás. *Hospital of Navarre, Oncology, Pamplona, Spain*

Background: By July 2000, we began a phase II prospective, single-institutional trial with chemo-radiation for locally advanced head and neck cancer (LA HNC).We present our preliminary results.

Matherial and methods: Treatment consisted of Radiation Therapy with the boost concomitant technique (72Gy/6w), and two cycles of concomitant cisplatin (20 mg/sqm/day, days 1-5 and 29-33). All patients received intravenous amifostine, 200 mg/m2 previously to the first fraction of irradiation, and their quality of life was also assessed before, during, and regularly after treatment. The endpoints of the study were overall survival, local control, and quality of life. There were 24 men and 1 woman, all stage IV of AJCC. Median age was 56 years (35-75 years). Primary sites were as follows: oropharynx, 7 patients(28%); nasopharynx, 2 (8%); hypopharynx, 7 (28%); larynx, 6 (24%); oral cavity, 1 (4%), and paranasal sinus, 2 (8%).

Results: According to the UICC criteria, twenty patients (80%) had complete response, two of these were found to have residual microscopic disease at neck dissection. One patient had partial response (4%), three patients did not response (12%), and one patient was not evaluated for response because he died while on therapy. 2-Year overall survival, disease free survival and local control (Kaplan-Meier) were 75%, 54%, and 67%, respectively. Acute toxicities were frequently severe. Ninety two per cent of patients had grade 3 or 4 mucositis. One patient died of treatment-related toxicity (sepsis and digestive hemorrhage. Five patients (20%) developed unexpected catheter-related venous thrombosis. Despite this acute toxicity, most patients completed their chemo-radiotherapy treatment at or near intended doses. This was facilitated by the administration of intensive supportive care. The quality of life scores reflect moderate limitations in global quality of life at the three assessment points, and in specific aspects in the second and third evaluations: insomnia, dry mouth, sticky saliva, coughing and sexuality. The other areas assessed reflect a good level.

Conclusions: This combined modality is a very active and toxic treatment for LAHNC. Nevertheless, it is probably that boost concomitant radiotherapy is not a good schema of irradiation for combining with chemotherapy in LAHNC, due to the elevated toxicity.

128 POSTER

Functional analysis of the larynx reconstructed with a vestibular fold flap after cordectomy

R.C. Mamede, H.M.A. Ricz, L.N. Aguiar-Ricz. *University of Sao Paulo/ Ribeirao Preto, Head and Neck Surgery, University Hospital, Facult, Ribeirao Preto/ SP, Brazil*

Objectives: Several reports of techniques for larynx reconstruction after partial vertical laryngectomy are available in the literature, some of them using structures of the larynx itself such as the vestibular fold, but few have emphasized analysis of laryngeal function after reconstruction. Thus, the objective of the present study was to assess laryngeal function in patients submitted to cordectomy followed by reconstruction with a vestibular fold flap.

Study Design: Prospective.

Methods: Ten patients, nine males and one female aged 45 to 75 years (mean age: 64.5 years), with glottis carcinomas treated by cordectomy and reconstructed with a vestibular fold flap were submitted to videolaryngostroboscopy for assessment of laryngeal permeability, flap positioning, laryngeal closure, aritenoid movement, characteristics of the sound source for speech (vibratile or frictional) and, when the source was vibratile, location and structures of the sound source.

Results: There was no need to maintain a tracheostomy during the late postoperative period since the reconstructed laryngeal lumen remained pervious. A vibratile sound source was detected in 90% of cases and was located in the glottic region in seven patients. The vestibular fold flap participated in the composition of the vibratile sound source in all cases.

Conclusions: Laryngeal reconstruction with a vestibular fold flap after cordectomy was able to maintain laryngeal function, providing laryngeal permeability and maintaining the organ as the air flow pathway, with full coaptation of laryngeal structures in 30% of cases, with a vibratile sound source in the glottic region in 70% of cases and with participation of the flap as a vibratile structure in 90% of cases.

129 POSTER

Induction chemotherapy (CT) followed by hyperfractionated radiation therapy (HFRT) in unresectable squamous cell carcinoma of the head and neck. Experience with an institutional protocol.

L. Heras[1], R. Mesia[1], M. Majem[1], R. Galiana[2], A. Montes[1], J. Nogues[3], A. Mari[4], X. Perez[1], F. Cardenal[1], J.R. Germa[1]. *[1] Institut Catala d'Oncologia, Medical Oncology, L'Hospitalet de Llobregat, Spain; [2] Institut Catala d'Oncologia, Radiation Oncology, L'Hospitalet de Llobregat, Spain; [3] Hospital Universitari de Bellvitge, Otorhinolaryngology, L'Hospitalet de Llobregat, Spain; [4] Hospital Universitari de Bellvitge, Oral and Maxillofacial Surgery, L'Hospitalet de Llobregat, Spain*

Introduction: Induction CT seems to increase survival in patients (pts) with unresectable squamous cell carcinoma of the head and neck up to 24% in 3-y overall survival. HfRT improves local control of disease in a 15%. This study evaluates the efficacy of our previous institutional protocol before introducing concurrent CT and RT as standard treatment in unresectable disease.

Material and Methods: We included all pts with unresectable disease from March/1994 to June/2002. Treatment schedule: CDDP 100mg/m^2 on day 1 + 5FU 1000 mg/m^2 c.i. on days 1 to 5 every 3 weeks for four courses followed by HfRT (1,2 Gy/fraction x 2 /day for a total dose of 76,8-79,2 Gy). A multidisciplinary committee undertook unresectability and response evaluation. Surgical neck dissection was planned for pts with persistent cervical nodes but complete primary tumour response.

Results: 99 pts were included. Median age: 55 [38-76]. All pts had stage IVM0 disease: T4 68%, N2-N3 89% and synchronic tumours 6%. 19% had previous tracheotomy. Tumour location: oropharynx 63%, hypopharynx 22%, oral cavity 8% and larynx 7%. Median interval between CT and HfRT: 29 days [0-113]. 41% presented grade 3-4 toxicity related to CT, mainly afebrile neutropenia and mucositis, but there were 5 pts (5%) with ischemic event. Grade 3-4 acute toxicity related to HfRT: 48% stomatitis (15% required enteral support), 21% epithelitis. Chronic toxicity related to HfRT: 6 emergency tracheotomy due to laryngeal edema, 5 pneumonia and 4-mucous/soft-tissue necrosis. There were 8 toxic deaths (2 CT, 6 HfRT). Final tumour response: Complete Response 54 pts, Partial Response 25 pts, Stable Disease 2 pts, Progressive Disease 9 pts and unevaluated 9 pts. Median follow-up: 28.3 months. From 54 pts with Complete Response, 22 are alive without disease, 19 pts have presented recurrence, 6 pts have died from non malignant reasons, 3 have died from second tumours and 4 pts were lost for follow-up without disease. The 3-year progression free survival was 36.2% [25.8 46.6] and the 3 and 5-year overall survival (OS) was 33.3% [23.4-43.2] and 23.6% [14.5-32.8] respectively.

Conclusion: Induction CT followed by HfRT increase OS rate in unresectable disease compared with those previously reported with RT alone or with Induction CT and conventional RT. However, the high acute toxicity rate needs a trained multidisciplinary support team. Chronic toxicity rate should be analysed by quality of life measurements in order to know if this benefit in survival is justified.

130 POSTER

Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group

Y. Eralp[1], A. Aydiner[1], A. Kizir[2], E. Kaytan[2], E.N. Oral[2], E. Topuz[1]. *[1] Istanbul University, Institute of Oncology, Medical Oncology, Istanbul, Turkey; [2] Istanbul University, Institute of Oncology, Radiation Oncology, Istanbul, Turkey*

Background: In this study we investigated the therapeutic outcome and prognostic factors in patients with resectable thymoma.

Procedure: Thirty-seven patients who underwent surgical resection for thymoma and referred to our clinic over the past decade were retrospectively analyzed. The median age was 41 years, ranging from 19 and 72 years. Myastenia gravis was observed in 28 patients (75.7%). The most frequent histologic subtype was epithelial (n: 21, 56.8%), followed by the lymphocytic type (n:6, 16.2%). Stage at presentation was distributed as stage I: 2 patients (5.4%), stage II: 19 patients (51.3%), stage III: 10 (27.0%) and stage IV: 4 patients (10.8%). The majority of the patients (n:33, 89.2%) had completely resectable disease, while 2 patients had microscopic and 2 more patients had macroscopic residual disease after surgery. Adjuvant radiotherapy was administered to 28 patients. One patient received adjuvant chemotherapy and 8 patients were followed with no adjuvant treatment.

Results: After a median follow-up period of 39 months, 6 patients (16.2%)experienced recurrence. There was a significant correlation between recurrence and adjuvant radiation therapy (2-sided p=0.0001), as well as